1
|
Yang A, Luo Y, Yang J, Xie T, Wang W, Wan X, Wang K, Pang D, Yang D, Dai H, Wu J, Meng S, Guo J, Wang Z, Shen S. Quantitation of Enterovirus A71 Empty and Full Particles by Sedimentation Velocity Analytical Ultracentrifugation. Viruses 2024; 16:573. [PMID: 38675915 PMCID: PMC11053756 DOI: 10.3390/v16040573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Revised: 04/02/2024] [Accepted: 04/04/2024] [Indexed: 04/28/2024] Open
Abstract
The enterovirus A71 (EV71) inactivated vaccine is an effective intervention to control the spread of the virus and prevent EV71-associated hand, foot, and mouth disease (HFMD). It is widely administered to infants and children in China. The empty particles (EPs) and full particles (FPs) generated during production have different antigenic and immunogenic properties. However, the antigen detection methods currently used were established without considering the differences in antigenicity between EPs and FPs. There is also a lack of other effective analytical methods for detecting the different particle forms, which hinders the consistency between batches of products. In this study, we analyzed the application of sedimentation velocity analytical ultracentrifugation (SV-AUC) in characterizing the EPs and FPs of EV71. Our results showed that the proportions of the two forms could be quantified simultaneously by SV-AUC. We also determined the repeatability and accuracy of this method and found that both parameters were satisfactory. We assessed SV-AUC for bulk vaccine quality control, and our findings indicated that SV-AUC can be used effectively to analyze the percentage of EPs and FPs and monitor the consistency of the process to ensure the quality of the vaccine.
Collapse
Affiliation(s)
- Anna Yang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Yun Luo
- The Research Core Facilities for Life Science (HUST), College of Life Science and Technology, Huazhong University of Science and Technology, Luoyu Road, Wuhan 430074, China
| | - Jie Yang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Tingbo Xie
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Wenhui Wang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Xin Wan
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Kaiwen Wang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Deqin Pang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Dongsheng Yang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Hanyu Dai
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Jie Wu
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Shengli Meng
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Jing Guo
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Zejun Wang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Shuo Shen
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| |
Collapse
|
2
|
Zhdanov DD, Ivin YY, Shishparenok AN, Kraevskiy SV, Kanashenko SL, Agafonova LE, Shumyantseva VV, Gnedenko OV, Pinyaeva AN, Kovpak AA, Ishmukhametov AA, Archakov AI. Perspectives for the creation of a new type of vaccine preparations based on pseudovirus particles using polio vaccine as an example. BIOMEDITSINSKAIA KHIMIIA 2023; 69:253-280. [PMID: 37937429 DOI: 10.18097/pbmc20236905253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2023]
Abstract
Traditional antiviral vaccines are currently created by inactivating the virus chemically, most often using formaldehyde or β-propiolactone. These approaches are not optimal since they negatively affect the safety of the antigenic determinants of the inactivated particles and require additional purification stages. The most promising platforms for creating vaccines are based on pseudoviruses, i.e., viruses that have completely preserved the outer shell (capsid), while losing the ability to reproduce owing to the destruction of the genome. The irradiation of viruses with electron beam is the optimal way to create pseudoviral particles. In this review, with the example of the poliovirus, the main algorithms that can be applied to characterize pseudoviral particles functionally and structurally in the process of creating a vaccine preparation are presented. These algorithms are, namely, the analysis of the degree of genome destruction and coimmunogenicity. The structure of the poliovirus and methods of its inactivation are considered. Methods for assessing residual infectivity and immunogenicity are proposed for the functional characterization of pseudoviruses. Genome integrity analysis approaches, atomic force and electron microscopy, surface plasmon resonance, and bioelectrochemical methods are crucial to structural characterization of the pseudovirus particles.
Collapse
Affiliation(s)
- D D Zhdanov
- Institute of Biomedical Chemistry, Moscow, Russia
| | - Yu Yu Ivin
- Institute of Biomedical Chemistry, Moscow, Russia; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia
| | | | | | | | | | - V V Shumyantseva
- Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia
| | - O V Gnedenko
- Institute of Biomedical Chemistry, Moscow, Russia
| | - A N Pinyaeva
- Institute of Biomedical Chemistry, Moscow, Russia; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia
| | - A A Kovpak
- Institute of Biomedical Chemistry, Moscow, Russia
| | - A A Ishmukhametov
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia
| | - A I Archakov
- Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia
| |
Collapse
|
3
|
Xu K, Sun H, Wang K, Quan Y, Qiao Z, Hu Y, Li C. The Quantification of Spike Proteins in the Inactivated SARS-CoV-2 Vaccines of the Prototype, Delta, and Omicron Variants by LC-MS. Vaccines (Basel) 2023; 11:vaccines11051002. [PMID: 37243106 DOI: 10.3390/vaccines11051002] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 05/12/2023] [Accepted: 05/15/2023] [Indexed: 05/28/2023] Open
Abstract
Developing variant vaccines or multivalent vaccines is a feasible way to address the epidemic as the SARS-CoV-2 variants of concern (VOCs) posed an increased risk to global public health. The spike protein of the SARS-CoV-2 virus was usually used as the main antigen in many types of vaccines to produce neutralizing antibodies against the virus. However, the spike (S) proteins of different variants were only differentiated by a few amino acids, making it difficult to obtain specific antibodies that can distinguish different VOCs, thereby challenging the accurate distinction and quantification of the variants using immunological methods such as ELISA. Here, we established a method based on LC-MS to quantify the S proteins in inactivated monovalent vaccines or trivalent vaccines (prototype, Delta, and Omicron strains). By analyzing the S protein sequences of the prototype, Delta, and Omicron strains, we identified peptides that were different and specific among the three strains and synthesized them as references. The synthetic peptides were isotopically labeled as internal targets. Quantitative analysis was performed by calculating the ratio between the reference and internal target. The verification results have shown that the method we established had good specificity, accuracy, and precision. This method can not only accurately quantify the inactivated monovalent vaccine but also could be applied to each strain in inactivated trivalent SARS-CoV-2 vaccines. Hence, the LC-MS method established in this study can be applied to the quality control of monovalent and multivalent SARS-CoV-2 variation vaccines. By enabling more accurate quantification, it will help to improve the protection of the vaccine to some extent.
Collapse
Affiliation(s)
- Kangwei Xu
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China
| | - Huang Sun
- Sinovac Life Sciences Co., Ltd., No. 21, Tianfu St., Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing 100050, China
| | - Kaiqin Wang
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China
| | - Yaru Quan
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China
| | - Zhizhong Qiao
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China
| | - Yaling Hu
- Sinovac Life Sciences Co., Ltd., No. 21, Tianfu St., Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing 100050, China
| | - Changgui Li
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, No. 2, Tiantan Xili, Dongcheng District, Beijing 100050, China
| |
Collapse
|
4
|
Dawson ED, Taylor AW, Johnson JE, Hu T, McCormick C, Thomas KN, Gao RY, Wahid R, Mahmood K, Rowlen KL. VaxArray immunoassay for the multiplexed quantification of poliovirus D-antigen. J Immunol Methods 2022; 504:113259. [PMID: 35314144 PMCID: PMC9072286 DOI: 10.1016/j.jim.2022.113259] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 03/11/2022] [Accepted: 03/14/2022] [Indexed: 11/19/2022]
Abstract
Next generation poliovirus vaccines are critical to reaching global poliovirus eradication goals. Recent efforts have focused on creating inactivated vaccines using attenuated Sabin strains that maintain patient safety benefits and immunogenicity of conventional inactivated vaccines while increasing manufacturing safety and lowering production costs, and on developing novel oral vaccines using modified Sabin strains that provide critical mucosal immunity but are further attenuated to minimize risk of reversion to neurovirulence. In addition, there is a push to improve the analytical tools for poliovirus vaccine characterization. Conventional and Sabin inactivated poliovirus vaccines typically rely on standard plate-based ELISA as in vitro D-antigen potency assays in combination with WHO international standards as calibrants. While widely utilized, the current D-antigen ELISA assays have a long time to result (up to 72 h), can suffer from lab-to-lab inconsistency due to non-standardized protocols and reagents, and are inherently singleplex. For D-antigen quantitation, we have developed the VaxArray Polio Assay Kit, a multiplexed, microarray-based immunoassay that uses poliovirus-specific human monoclonal antibodies currently under consideration as standardized reagents for characterizing inactivated Sabin and Salk vaccines. The VaxArray assay can simultaneously quantify all 3 poliovirus serotypes with a time to result of less than 3 h. Here we demonstrate that the assay has limits of quantification suitable for both bioprocess samples and final vaccines, excellent reproducibility and precision, and improved accuracy over an analogous plate-based ELISA. The assay is suitable for adjuvanted combination vaccines, as common vaccine additives and crude matrices do not interfere with quantification, and is intended as a high throughput, standardized quantitation tool to aid inactivated poliovirus vaccine manufacturers in streamlining vaccine development and manufacturing, aiding the global polio eradication effort. Multiplexed D-antigen immunoassay for all 3 poliovirus serotypes Has <3 h time to result and compares well to 3-day plate-based ELISA Assay shows high specificity and is reactive to sIPV, cIPV, and OPV Applicable to in-process samples, final IPV and combination vaccine formulations High accuracy and precision for both sIPV and cIPV over multiple users and days
Collapse
Affiliation(s)
- Erica D Dawson
- InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA.
| | - Amber W Taylor
- InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA
| | - James E Johnson
- InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA
| | - Tianjing Hu
- InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA
| | | | - Keely N Thomas
- InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA
| | - Rachel Y Gao
- InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA
| | | | | | - Kathy L Rowlen
- InDevR, Inc., 2100 Central Ave., Suite 106, Boulder, CO 80301, USA
| |
Collapse
|
5
|
Westdijk J, Kogelman A, van der Put R, Eksteen Z, Suarez D, Kersten GFA, Metz B, Danial M. Immunochemical and Biophysical Characterization of Inactivated Sabin Poliovirus Products: Insights into Rapid Quality Assessment Tools. J Pharm Sci 2022; 111:1058-1069. [PMID: 35114211 DOI: 10.1016/j.xphs.2022.01.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 01/28/2022] [Accepted: 01/28/2022] [Indexed: 10/19/2022]
Abstract
The aim of this study was to demonstrate the strength of combining immunochemical and biophysical analysis tools for assessing the quality of Sabin inactivated poliovirus vaccine (Sabin-IPV) bulk products. We assessed Sabin-IPV serotypes 1, 2 and 3 from six different manufacturers and evaluated their comparability through biosensor analysis and biophysical characterization methods, including tryptophan fluorescence and asymmetrical flow field-flow fractionation - multi-angle light scattering analysis. These methods enabled us to assess antigenic as well as conformational and structural integrity profiles, respectively. Based on Sabin-IPV samples that were subjected to accelerated storage conditions, we revealed that existing immunochemical methods exhibit remarkably similar trends to the results obtained by the biophysical characterization methods. While the results underpin that the comparability of Sabin-IPV bulk products of different manufacturers is poor, information about their quality can rapidly be obtained by using both immunochemical and biophysical methods. Furthermore, the study highlights that quality assessment of Sabin-IPV can be obtained through biophysical techniques can complement the assessments performed with monoclonal antibodies and suggests that similar techniques could be employed to characterize other enteroviruses.
Collapse
Affiliation(s)
- Janny Westdijk
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands.
| | - Amy Kogelman
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Robert van der Put
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Zaskia Eksteen
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Diego Suarez
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Gideon F A Kersten
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands; Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC Leiden, The Netherlands
| | - Bernard Metz
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Maarten Danial
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands.
| |
Collapse
|
6
|
Geurink L, van Tricht E, van der Burg D, Scheppink G, Pajic B, Dudink J, Sänger-van de Griend C. Sixteen capillary electrophoresis applications for viral vaccine analysis. Electrophoresis 2021; 43:1068-1090. [PMID: 34739151 DOI: 10.1002/elps.202100269] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 10/14/2021] [Accepted: 10/25/2021] [Indexed: 12/14/2022]
Abstract
A broad range of CE applications from our organization is reviewed to give a flavor of the use of CE within the field of vaccine analyses. Applicability of CE for viral vaccine characterization, and release and stability testing of seasonal influenza virosomal vaccines, universal subunit influenza vaccines, Sabin inactivated polio vaccines (sIPV), and adenovirus vector vaccines were demonstrated. Diverse CZE, CE-SDS, CGE, and cIEF methods were developed, validated, and applied for virus, protein, posttranslational modifications, DNA, and excipient concentration determinations, as well as for the integrity and composition verifications, and identity testing (e.g., CZE for intact virus particles, CE-SDS application for hemagglutinin quantification and influenza strain identification, chloride or bromide determination in process samples). Results were supported by other methods such as RP-HPLC, dynamic light scattering (DLS), and zeta potential measurements. Overall, 16 CE methods are presented that were developed and applied, comprising six adenovirus methods, five viral protein methods, and methods for antibodies determination of glycans, host cell-DNA, excipient chloride, and process impurity bromide. These methods were applied to support in-process control, release, stability, process- and product characterization and development, and critical reagent testing. Thirteen methods were validated. Intact virus particles were analyzed at concentrations as low as 0.8 pmol/L. Overall, CE took viral vaccine testing beyond what was previously possible, improved process and product understanding, and, in total, safety, efficacy, and quality.
Collapse
Affiliation(s)
- Lars Geurink
- Janssen Vaccines and Prevention B.V., CN Leiden, The Netherlands.,Department of Medicinal Chemistry, Faculty of Pharmacy, Biomedical Centre, Uppsala University, Uppsala, Sweden
| | - Ewoud van Tricht
- Janssen Vaccines and Prevention B.V., CN Leiden, The Netherlands
| | | | - Gerard Scheppink
- Janssen Vaccines and Prevention B.V., CN Leiden, The Netherlands
| | - Bojana Pajic
- Janssen Vaccines and Prevention B.V., CN Leiden, The Netherlands
| | - Justin Dudink
- Janssen Vaccines and Prevention B.V., CN Leiden, The Netherlands
| | - Cari Sänger-van de Griend
- Janssen Vaccines and Prevention B.V., CN Leiden, The Netherlands.,Department of Medicinal Chemistry, Faculty of Pharmacy, Biomedical Centre, Uppsala University, Uppsala, Sweden.,Kantisto B.V., Baarn, The Netherlands
| |
Collapse
|
7
|
Wang Y, Xu Q, Jeyaseelan V, Ying Z, Mach O, Sutter R, Wen N, Rodewald L, Li C, Wang J, Yuan H, Yin Z, Feng Z, Xu A, An Z. Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial. THE LANCET REGIONAL HEALTH. WESTERN PACIFIC 2021; 10:100133. [PMID: 34327346 PMCID: PMC8315596 DOI: 10.1016/j.lanwpc.2021.100133] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 02/22/2021] [Accepted: 03/04/2021] [Indexed: 11/24/2022]
Abstract
BACKGROUND We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8-11 months of age). Poliovirus neutralizing antibodies were measured in sera collected prior to the first sIPV dose and one month after the last dose. FINDINGS We enrolled 560 infants; 536 (95.7%) completed the study. Final seropositivity rates were >98% for all three serotypes in both study arms. There were no statistically significant differences in seropositivity between the 2-dose and the 3-dose schedule. Final median reciprocal titres of polio antibodies were high overall (>1:768 for all serotypes) and statistically significantly higher in 2-dose recipients compared with 3-dose recipients (p < 0.001). INTERPRETATION This study offers evidence that two doses of sIPV administered at 4 and 8-11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. Median reciprocal titres of polio antibodies were high overall, and were more related to the interval between doses than the number of doses, with the longer interval of the 2-dose schedule producing higher reciprocal titres than the shorter-interval 3-dose schedule. The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule. Countries planning to use an IPV-only schedule in the post-eradication era can consider this 2-dose sIPV option as an immunogenic and dose-sparing strategy. FUNDING World Health Organization (from a grant from International PolioPlus Committee, Rotary International, Evanston, IL, USA).
Collapse
Affiliation(s)
- Yamin Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qing Xu
- Shandong Provincial Center for Disease Control and Prevention, Jinan, China
| | - Vishali Jeyaseelan
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Zhifang Ying
- National Institutes for Food and Drug Control, Beijing, China
| | - Ondrej Mach
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Roland Sutter
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Ning Wen
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Changgui Li
- National Institutes for Food and Drug Control, Beijing, China
| | - Jie Wang
- Dezhou prefecture-level Center for Disease Control and Prevention, Dezhou, Shandong, China
| | - Hui Yuan
- Liaocheng prefecture-level Center for Disease Control and Prevention, Liaocheng, Shandong, China
| | - Zundong Yin
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Aiqiang Xu
- Shandong Provincial Center for Disease Control and Prevention, Jinan, China
| | - Zhijie An
- Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
8
|
Human IgA Monoclonal Antibodies That Neutralize Poliovirus, Produced by Hybridomas and Recombinant Expression. Antibodies (Basel) 2020; 9:antib9010005. [PMID: 32121092 PMCID: PMC7148538 DOI: 10.3390/antib9010005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2020] [Revised: 02/01/2020] [Accepted: 02/11/2020] [Indexed: 12/13/2022] Open
Abstract
Poliovirus (PV)-specific intestinal IgAs are important for cessation of PV shedding in the gastrointestinal tract following an acute infection with wild type or vaccine-derived PV strains. We sought to produce IgA monoclonal antibodies (mAbs) with PV neutralizing activity. We first performed de novo IgA discovery from primary human B cells using a hybridoma method that allows assessment of mAb binding and expression on the hybridoma surface: On-Cell mAb Screening (OCMS™). Six IgA1 mAbs were cloned by this method; three potently neutralized type 3 Sabin and wt PV strains. The hybridoma mAbs were heterogeneous, expressed in monomeric, dimeric, and aberrant forms. We also used recombinant methods to convert two high-potency anti-PV IgG mAbs into dimeric IgA1 and IgA2 mAbs. Isotype switching did not substantially change their neutralization activities. To purify the recombinant mAbs, Protein L binding was used, and one of the mAbs required a single amino acid substitution in its κ LC in order to enable protein L binding. Lastly, we used OCMS to assess IgA expression on the surface of hybridomas and transiently transfected, adherent cells. These studies have generated potent anti-PV IgA mAbs, for use in animal models, as well as additional tools for the discovery and production of human IgA mAbs.
Collapse
|